Use of the NuvaRing® hormone-releasing system in late reproductive-age women with type 1 diabetes mellitus

Grigoryan, O. R.; Grodnitskaya, E E; Андреева, Елена; Chebotnikova, T V; Мельниченко, Г. А.

doi:10.1080/09513590701708795

Cited by 20 publications

(4 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been shown to be a safe form of contraception in late-reproductive-age women with type 1 diabetes mellitus, as no clinically significant effect on carbohydrate metabolism was seen, compared with the control group of age-matched women with type 1 diabetes mellitus using no contraception 34. Also in a comparative study, insulin sensitivity significantly decreased during COC use and tended to increase during vaginal administration of hormonal contraceptives 33…”

Section: Safetymentioning

confidence: 99%

Examining the efficacy, safety, and patient acceptability of the combined contraceptive vaginal ring (NuvaRing®)

Wieder

Pattimakiel²

2010

IJWH

View full text Add to dashboard Cite

The contraceptive vaginal ring is a novel contraceptive method that offers unique advantages. Intravaginal delivery of both estrogen and progesterone allows continuous release of medication, resulting in lower systemic levels. The use of long-term combined hormonal contraception enables improved cycle control compared with progesterone-only methods. The indications and usage of the NuvaRing® are described along with the efficacy, tolerability, and safety. Overall, the contraceptive vaginal ring appears to be very effective, with a favorable side-effect profile, and is highly acceptable to most patients.

show abstract

Section: Safetymentioning

confidence: 99%

Examining the efficacy, safety, and patient acceptability of the combined contraceptive vaginal ring (NuvaRing®)

Wieder

Pattimakiel²

2010

IJWH

View full text Add to dashboard Cite

show abstract

“…During 1999-2008, the percentage of women aged 20-44 years with undiagnosed diabetes was 0.5% (85). Although hormonal contraceptives can have some adverse effects on glucose metabolism in healthy and diabetic women, the overall clinical effect is minimal (171)(172)(173)(174)(175)(176)(177).…”

Section: Examinations and Tests Needed Before Initiation Of An Injectmentioning

confidence: 99%

U.S. Selected Practice Recommendations for Contraceptive Use, 2016

Curtis

Jatlaoui²,

Tepper³

et al. 2016

MMWR Recomm. Rep.

346

351

View full text Add to dashboard Cite

The 2016 U.S. Selected Practice Recommendations for Contraceptive Use (U.S. SPR) addresses a select group of common, yet sometimes controversial or complex, issues regarding initiation and use of specific contraceptive methods. These recommendations for health care providers were updated by CDC after review of the scientific evidence and consultation with national experts who met in Atlanta, Georgia, during August 26-28, 2015. The information in this report updates the 2013 U.S. SPR (CDC. U.S. selected practice recommendations for contraceptive use, 2013. MMWR 2013;62[No. RR-5]). Major updates include 1) revised recommendations for starting regular contraception after the use of emergency contraceptive pills and 2) new recommendations for the use of medications to ease insertion of intrauterine devices. The recommendations in this report are intended to serve as a source of clinical guidance for health care providers and provide evidence-based guidance to reduce medical barriers to contraception access and use. Health care providers should always consider the individual clinical circumstances of each person seeking family planning services. This report is not intended to be a substitute for professional medical advice for individual patients. Persons should seek advice from their health care providers when considering family planning options.

show abstract

“…Reasons for exclusion were that five publications were case-control studies (Diab 2000;Grigoryan 2008;Petersen 1994;Petersen 1995;Petersen 1996); one article was a review (Skouby 1986b); one article was a case report (Reder 1967); one study was a nonrandomised prospective follow-up study (Klein 1999b); one study (Aznar 1976) was performed randomly but included patient with a single impaired glucose intolerance test and no diabetes mellitus was diagnosed during the trial; one study was only randomised for di erent regimens of using a vaginal ring and did not randomise for di erent types of contraceptives (Grodnitskaya 2010).…”

Section: Excluded Studiesmentioning

confidence: 99%

Hormonal versus non-hormonal contraceptives in women with diabetes mellitus type 1 and 2

Visser

Snel

Vliet

2013

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

The four included randomised controlled trials in this systematic review provided insufficient evidence to assess whether progestogen-only and combined contraceptives differ from non-hormonal contraceptives in diabetes control, lipid metabolism and complications. Three of the four studies were of limited methodological quality, sponsored by pharmaceutical companies and described surrogate outcomes. Ideally, an adequately reported, high-quality randomised controlled trial analysing both intermediate outcomes (that is glucose and lipid metabolism) and true clinical endpoints (micro- and macrovascular disease) in users of combined, progestogen-only and non-hormonal contraceptives should be conducted. However, due to the low incidence of micro- and macrovascular disease and accordingly the large sample size and long follow-up period needed to observe differences in risk, a randomised controlled trial might not be the ideal design.

show abstract

Use of the NuvaRing® hormone-releasing system in late reproductive-age women with type 1 diabetes mellitus

Abstract: The NuvaRing hormone-releasing system proved to be a reliable and safe means of contraception for late reproductive-age women with type 1 DM.

Cited by 20 publications

References 13 publications

Examining the efficacy, safety, and patient acceptability of the combined contraceptive vaginal ring (NuvaRing®)

Examining the efficacy, safety, and patient acceptability of the combined contraceptive vaginal ring (NuvaRing®)

U.S. Selected Practice Recommendations for Contraceptive Use, 2016

Hormonal versus non-hormonal contraceptives in women with diabetes mellitus type 1 and 2

Contact Info

Product

Resources

About

Use of the NuvaRing® hormone-releasing system in late reproductive-age women with type 1 diabetes mellitus

Abstract: The NuvaRing hormone-releasing system proved to be a reliable and safe means of contraception for late reproductive-age women with type 1 DM.

Cited by 20 publications

References 13 publications

Examining the efficacy, safety, and patient acceptability of the combined contraceptive vaginal ring (NuvaRing&reg;)

Examining the efficacy, safety, and patient acceptability of the combined contraceptive vaginal ring (NuvaRing&reg;)

U.S. Selected Practice Recommendations for Contraceptive Use, 2016

Hormonal versus non-hormonal contraceptives in women with diabetes mellitus type 1 and 2

Contact Info

Product

Resources

About

Examining the efficacy, safety, and patient acceptability of the combined contraceptive vaginal ring (NuvaRing®)

Examining the efficacy, safety, and patient acceptability of the combined contraceptive vaginal ring (NuvaRing®)